Скачать или смотреть SABCS 2022: DESTINY-Breast02 + DESTINY-Breast03

Ian Krop, MD, PhD, Smilow Cancer Hospital, Yale New Haven, CT, shares his key takeaways from the San Antonio Breast Cancer Symposium (SABCS) 2022, including how the data from the Phase III DESTINY-Breast02 (NCT03523585) trial fit into the larger context of trastuzumab deruxtecan (T-DXd) in HER2-posititve metastatic breast cancer. The Phase III DESTINY-Breast03 (NCT03529110), investigating trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer in the second-line setting, whereas DESTINY-Breast02 investigated T-DXd in later lines. In the second-line, DESTINY-Breast03 demonstrated a progression-free survival (PFS) four times longer with T-DXd than with T-DM1, a 28-month median PFS versus approximately 7 months, respectively, as well as an improved overall-survival (OS), supporting the use of T-DXd in the second-line setting. However, for patients who have already received T-DM1, as per previous protocol, and have yet to receive T-DXd, the DESTINY-Breast02 trial supports the use of T-DXd. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.